Praxis Precision Medicines prices $661M equity offering at $260/share, net proceeds ~$621M

Praxis Precision Medicines, Inc.

Offering of 2,212,000 shares plus full exercise of underwriter option for 331,800 shares at $260/share.
Net proceeds estimated at $621.2M after underwriting discounts and expenses.
Underwriters: Piper Sandler, TD Securities, Guggenheim Securities; closing expected Jan 8, 2026.
Proceeds to fund commercialization prep, R&D, and working capital; cash runway extended into 2028.
Offering made under effective shelf registration (Form S-3 ASR filed Dec 23, 2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.